» Sign in / Register


Interleukin-6, B-cell hybridoma growth factor

murine, recombinant, E. coli

Cat. No. Amount Price (EUR) Buy / Note
PR-467 10 μg 253,00 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 22 kDa

Accession number: P08505

Accession number: P08505

Purity: > 90 % (SDS-PAGE)

Form: lyophilised (IL-6 is lyophilised from a 1 mg/ml solution containing 10 mM NaAcetate pH 6.0)

Solubility: It is recommended to reconstitute the lyophilised Interleukin 6 in 20 mM HCl to 0.1-1.0 mg/ml to regain full activity and can then be further diluted to other aqueous solutions. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Activity: ED50: < 0.02 ng/ml, corresponding to a specific activity 5 x 107 IU/mg, determined by the dosedependent stimulation of murine 7TD1 cells.

IL-6 is a variably glycosylated protein produced by many different cells, but the main sources in vivo are stimulated monocytes/macrophages, fibroblasts, and vascular endothelial cells, indicative of its role in the modulation of the immune system. Other cells known to express IL-6 include keratinocytes, osteoblasts, T-cells, B-cells, neutrophils, eosinophils, mast cells, smooth muscle cells, and skeletal muscle cells. Typical stimuli for IL-6 production are IL-1, TNF-α, and bacterial endotoxin. Recombinant murine IL-6 produced in E. coli is a single, non-glycosylated polypeptide chain containing 187 amino acids and having a molecular mass of 21.7 kDa. IL-6 is purified by proprietary chromatographic techniques.

Endotoxin: Less than 0.1 ng/μg (IEU/μg) of IL-6.

Amino acid sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Phe-Pro-Thr-Ser.

Selected References:
Lu et al. (2011) 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated disruption of the CD40 ligand-induced activation of primary human B cells. Toxicology and Applied Pharmacology 255 (3):251.
Lu et al. (2009) Establishment of an Immunoglobulin M Antibody-Forming Cell Response Model for Characterizing Immunotoxicity in Primary Human B Cells. Toxicological Sciences 112 (2):363.
Meads et al. (2004) Kaposi'ssarcomaassociated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J. Biol. Chem. 279:51793.
Saha et al. (2003) Two novel somatic mutations in the human interleukin 6 promoter region in a patient with sporadic breast cancer. Eur. J. Immunogenet. 30:397.
Matthews et al. (2003) Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278:38829.
Li et al. (2003) Effect of in situ expression of human interleukin-6 on antibody responses against Salmonella typhimurium antigens. FEMS Immunol. Med. Microbiol. 37:135.
Febbraio et al. (2002) Muscle-derived interleukin- 6: mechanisms for activation and possible biological roles. FASEB J. 16:1335.
Varghese et al. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Proc. Natl. Acad. Sci. USA. 99:15959.
Song et al. (2002) Human interleukin-6 induces human herpesvirus- 8 replication in a body cavity-based lymphoma cell line. J. Med. Virol. 68:404.